ScreenerHero

ALTHX THX Pharma

EPA · FR · Healthcare · Biotechnology · theranexus.com
3.160EUR-7.06%Mkt Cap: 49.77M $P/E: —

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap49.77M USD
Enterprise Value42.08M USD
Revenue (TTM)876.14K USD
Gross Profit-2.55M USD
Net Income (TTM)-3.26M USD
Revenue/Share0.06 EUR
Last Price3.160 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.72
PEG—
EV/EBITDA-9.82
EV/Revenue48.03
P/S56.80
P/B15.05
EPS (TTM)-0.21
EPS (Forward)-1.84
52W Range
1.49046% of range5.100
52W High5.100 EUR
52W Low1.490 EUR
Profitability
Gross Margin-177.00%
Oper. Margin-144876610.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-103.45%
ROA-28.46%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-893.04K USD
CapEx (TTM)279.60K USD
FCF Margin-364.26%
FCF Yield-6.41%
Net Debt-5.31M USD
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.99
Current Ratio2.35
Quick Ratio2.32
Book Value/Sh0.21 EUR
Cash/Share0.56 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.800 EUR
Upside (mean)+83.5%
Target Range5.800 EUR – 5.800 EUR
# Analysts1
Ownership
Shares Out.14.49M
Float13.13M
Insiders12.84%
Institutions19.71%
Technical
SMA 503.893 (-18.8%)
SMA 2003.308 (-4.5%)
Beta1.51
S&P 52W Chg14.58%
Avg Vol (30d)83.85K
Avg Vol (10d)73.80K
Technical Indicators
RSI (14)33.0
MACD-0.1454
MACD Signal-0.1581
MACD Hist.+0.0128
BB Upper3.721 EUR
BB Middle3.405 EUR
BB Lower3.089 EUR
BB Width18.57%
ATR (14)0.1837 EUR
Vol Ratio (20d)1.82x